Novelty detection (ND) has gained attention in many applications for its effectiveness in dealing with imbalanced data. Many ND algorithms have been proposed. For example, the level set boundary description (LSBD) algorithm can accurately estimate a boundary around normal data which is subsequently used to detect novelties. However, the computational complexity and the convergence time of the LSBD algorithms increases substantially when data dimensionality increases. To solve those challenges, we propose an Integrated Autoencoder-Level Set Method (AE-LSM) for ND in this paper. The AE structure is employed to reduce the feature space with high dimensionality to a 3-dimensional (3D) space. The LSM algorithm is trained based on the compressed 3D data to identify the boundary of normal data. The AE-LSM has advantages of boundary control and good generalization performance. Experiments on 5 benchmark UCI datasets and an Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset demonstrate that the proposed AE-LSM present a 3%~14% significant improvement based on the average AUC (p<0.05) over the AE and LSBD algorithms across the six datasets.
|Title of host publication||2022 International Joint Conference on Neural Networks (IJCNN)|
|Number of pages||8|
|ISBN (Electronic)||978-1-7281-8671-9, 978-1-6654-9526-4|
|Publication status||Published (in print/issue) - 30 Sep 2022|
|Event||IEEE WORLD CONGRESS ON COMPUTATIONAL INTELLIGENCE - Italy, Padua, Italy|
Duration: 18 Jul 2022 → 23 Jul 2022
|Conference||IEEE WORLD CONGRESS ON COMPUTATIONAL INTELLIGENCE|
|Period||18/07/22 → 23/07/22|
Bibliographical noteFunding Information:
Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
We are grateful for access to the Tier 2 High Performance Computing resources provided by the Northern Ireland High-Performance Computing (NI-HPC) facility funded by the UK Engineering and Physical Sciences Research Council (EPSRC), Grant Nos. EP/T022175/ and EP/W03204X/1. DC is grateful for the UKRI Turing AI Fellowship 2021-2025 funded by the EPSRC (grant number EP/V025724/1). This project was supported by Vice Chancellor Research Scholarship, Ulster University, the Alzheimer's Research UK NI Networking, and the Global Challenges Research Fund Networking.
© 2022 IEEE.
- Novelty Detection
- Level set method
- Level set boundary description
- novelty detection
- level set boundary description
- level set methods